Abstract 5581
Background
MDNA55, a novel Interleukin-4 empowered cytokine fused to Pseudomonas exotoxin, binds to IL-4 receptor (IL-4R) overexpressed by GB and immunosuppressive cells of the tumor microenvironment. Understanding biological effects of MDNA55 and defining their time course requires multi-modal imaging. Consecutive increases in tumor size defined by Response Assessment in Neuro-Oncology (RANO) can result in premature withdrawal of subjects prior to evaluation of clinical benefit. Standard tumor response tools need optimizing for localized immunotherapies to capture delayed treatment benefit.
Methods
MDNA55-05 is a 52 subject, open-label, non-randomized, study of intratumoral delivery of ≤ 240 μg MDNA55 via ≤ 4 catheters in a single treatment in GB at 1st or 2nd recurrence, tumors ≤ 4 cm. Multimodality MRI determines tissue response and disease status using RANO-based criteria, combining contrast-enhanced and perfusion imaging.
Results
27 subjects, median age 51 (35 - 77) received 18 – 180 mg MDNA55. Prior treatments included surgery (N = 26), radiation (N = 25) and temozolomide (N = 25). Review of some early post-treatment MRIs show extensive changes to enhancement which could increase for up to 120 days then take another 6 months to resolve. Multi-modal MRI helps differentiate changes due to progression from local tissue reactions (pseudoprogression). Response patterns seen include early progression, early onset response and delayed onset response. Withdrawal of subjects without differentiating pseudoprogression from true progression can preclude the ability to fully assess therapeutic effect. A refined MDNA55 evaluation regimen consisting of multi-modal MRI and/or biopsies has been implemented to optimize the chance for increased therapeutic benefit.
Conclusions
These findings show biologic activity of MDNA55 in recurrent GB with appearances on imaging suggestive of disease control in some subjects. We illustrate how supportive diagnostic modalities are required for accurate response assessments and argue the importance of refining overall response tools according to treatment type.
Clinical trial identification
NCT02858895.
Legal entity responsible for the study
Medicenna Therapeutics.
Funding
Medicenna Therapeutics.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4302 - Impact of a molecular prescreening program (MPP) in the management of patients with non-glioblastoma brain tumors.
Presenter: José Carlos Benítez Montañez
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
5076 - Multiplex digital PCR for the diagnostic of pilocytic astrocytoma and glioneuronal tumors
Presenter: Fr_d_ric Fina
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
Poster Discussion session - CNS tumours - Invited Discussant 376PD and 377PD
Presenter: Michael Weller
Session: Poster Discussion session - CNS tumours
Resources:
Slides
Webcast
3570 - Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases
Presenter: Christoph Wippel
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
4352 - Androgen receptor expression in breast cancer brain metastases
Presenter: Elisabeth Bergen
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
Poster Discussion session - CNS tumours - Invited Discussant 378PD and 379PD
Presenter: Priscilla Brastianos
Session: Poster Discussion session - CNS tumours
Resources:
Slides
4497 - Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): a mono-institutional experience
Presenter: Giuseppe Lombardi
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
Slides
5284 - Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
Presenter: Joana Simões
Session: Poster Discussion session - CNS tumours
Resources:
Abstract
Poster Discussion session - CNS tumours - Invited Discussant 380PD, 381PD and 382PD
Presenter: Frank Winkler
Session: Poster Discussion session - CNS tumours
Resources:
Slides
Webcast